EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).

Two new molecular entities, Lundbeck's Selincro (nalmefene) for the treatment of alcoholism and Roche's Perjeta (pertuzumab) for breast cancer, and a new antipsychotic formulation, Alexza Pharmaceuticals Inc.'s Adasuve (inhaled loxapine) were granted positive opinions Dec. 14 by Europe's Committee for Medicinal Products for Human Use (CHMP).

However, [Genzyme BV]/Ionis Pharmaceuticals Inc.'s antisense lipid-lowering therapy Kynamro (mipomersen) and Vanda Pharmaceuticals Inc.’s atypical antipsychotic Fanaptum (oral...

More from Europe

More from Geography